Skip to main content
. 2020 Aug 3;44(4):1627–1637. doi: 10.3892/or.2020.7714

Figure 2.

Figure 2.

Effects of miR-137 and miR-210 on cell cycle distribution, cell viability, cell stemness and apoptosis. (A) The effects of miR-137 mimics or miR-210 inhibitor on cell cycle phases were measured by performing flow cytometry after PI staining (left panel). Cell cycle phases by statistical analysis (right panel). *P<0.05 vs. NC mimics group; #P<0.05, vs. NC inhibitor group. (B) Cell viability analysis was carried out by performing CCK-8 assay after transfection of miR-137 mimics or miR-210 inhibitor into BCSCs. *P<0.05 vs. NC mimics group or NC inhibitor group. (C) ALDH-positive subpopulation of BCSCs after transfection of miR-137 mimics or miR-210 inhibitor was measured by flow cytometric analysis. *P<0.05 vs. NC mimics group or NC inhibitor group. (D) Apoptotic cell death was assessed out by performing Annexin V/PI double staining after transfection of miR-137 mimics or miR-210 inhibitor (left panel). Apoptotic cell death by statistical analysis (right panel). *P<0.05 vs. NC mimics group or NC inhibitor group. BCSCs, breast cancer stem-like cells; ALDH, aldehyde dehydrogenase; NC, negative control.